An enhanced anti-tumor response at the primary site—as well as an abscopal effect—was observed when fractionated radiotherapy was combined with an anti-CTLA-4 monoclonal antibody in a murine colon cancer model MCA38 [17]. Here, CTLA4 is linked to neoplasm.